What do clinical trials to date tell us about the treatment of pulmonary sarcoidosis?

What do clinical trials to date tell us about the treatment of pulmonary sarcoidosis?

Publication date on this website: 7 October 2026.
Date of the original paper: September 2026.

Introduction
A review in the journal Pulmonary Therapy analyzes clinical trials of treatments for pulmonary sarcoidosis and explains why treatment decisions could not, for a long time, rely on sufficiently strong randomized evidence. The authors highlight a shift toward steroid-sparing strategies, biomarkers, and personalized treatment.

Extended summary
Sarcoidosis most commonly affects the lungs and mediastinal lymph nodes, but its course can vary considerably. Corticosteroids have been the mainstay of treatment for decades, largely on the basis of observational data and expert consensus. A review of recent trials shows that a higher prednisone dose is not necessarily more beneficial than a lower dose when appropriate patients are assessed, while methotrexate may be a steroid-sparing initial option in certain situations.

For patients who do not respond sufficiently to initial treatment, medicines targeting individual inflammatory pathways and medicines developed for other fibrotic lung diseases are being investigated. Results have not been consistent across all studies. The authors caution that a negative trial result may sometimes reflect patient selection, study duration, concomitant treatment, or inconsistent outcomes, rather than a complete absence of biological effect.

What is new
The review does not present one new treatment for routine use; instead, it synthesizes how the evidence base is developing. It particularly emphasizes the need for international collaborative trials, reliable measures of disease activity, and biomarkers that could enable treatment selection for individual patients.

Why it matters to people with sarcoidosis and clinicians
For people with sarcoidosis, the text helps explain why treatment cannot be determined solely by the name of a medicine or a single test result. For clinicians, the review is a reminder of the importance of comparing lung function, symptoms, radiological changes, quality of life, and treatment side effects. Starting or changing treatment must be based on an individual assessment, not on the results of a single study.

Limitations of the evidence
This is a review article covering studies with different designs, durations, and outcomes. Some trials included patients whose disease was already well controlled with corticosteroids, which can make it more difficult to demonstrate additional benefit. The results cannot automatically be applied to patients with other organ manifestations or a different level of disease severity.

Conclusion
Evidence on the treatment of pulmonary sarcoidosis is becoming stronger, but it is still incomplete. Development is moving toward steroid-sparing treatment, clear clinical outcomes, and treatment selection according to each patient's phenotype and risk.

Source and bibliographic details
Zapata-Huizi JJ, Herrera-Tamayo M, Ríos-Poveda JJ, et al. Sarcoidosis: A Clinical Trials Perspective. Pulmonary Therapy. 2026;12(3):785–804. DOI: 10.1007/s41030-026-00372-z.
Source: https://pubmed.ncbi.nlm.nih.gov/42418148/

Medical note
This text is for informational purposes and does not replace a medical examination, diagnosis, or individualized advice. Do not start, stop, or change treatment independently. Discuss treatment choices with the doctor who knows your lung function, symptoms, and other findings.